Last reviewed · How we verify
NCT07521449: PS-DHA-ADHD
Effects of Phosphatidylserine and DHA on Cognitive Performance in Children With ADHD
NA trial testing Placebo in Attention Deficit Hyperactivity Disorder (ADHD) in 45 participants. Completed in 1 June 2025.
1 June 2024
Quick facts
| Lead sponsor | Çağlar Charles Daniel Jaicks |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 30 December 2023 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Placebo
- Phosphatidylserine-Omega3 — full drug profile →
- Phosphatidylserine-Omega3 — full drug profile →
- DHA Omega-3 — full drug profile →
Conditions studied
- Attention Deficit Hyperactivity Disorder (ADHD) — all drugs for Attention Deficit Hyperactivity Disorder (ADHD) →
- ADHD — all drugs for ADHD →
Sponsor
Çağlar Charles Daniel Jaicks
Who can join
Adults 10 to 14, any sex, with Attention Deficit Hyperactivity Disorder (ADHD) or ADHD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to evaluate the effects of different phosphatidylserine (PS) formulations, with or without docosahexaenoic acid (DHA), on cognitive performance in children diagnosed with attention-deficit/hyperactivity disorder (ADHD) or presenting with clinically significant subthreshold ADHD symptoms. A total of 45 medication-naïve children aged 10-14 years were randomly assigned to one of four groups: placebo, PS capsule (PS + DHA), PS sachet (PS without DHA), or PS Plus capsule (higher-dose PS + DHA). The intervention period was eight weeks. Cognitive performance was assessed at baseline and after the intervention using the MOXO continuous performance test and the Stroop test. The study aimed to compare the effects of different PS formulations on attention, impulsivity, hyperactivity, and executive function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07521449
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Attention Deficit Hyperactivity Disorder (ADHD)
Currently open trials in the same condition.
- NCT06853665 — The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine · Phase 4 · recruiting
- NCT07189442 — L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD · NA · recruiting
- NCT06960980 — Improving ADHD Teen Driving - Virtual Reality · NA · recruiting
- NCT06810180 — Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Het · NA · recruiting
- NCT06885060 — Exploring Eye Vergence Markers ADHD) and ASD · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07521449 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Çağlar Charles Daniel Jaicks
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07521449.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing